Immunome, Inc. (IMNM)
18.29
-0.47
(-2.51%)
USD |
NASDAQ |
Oct 29, 16:00
18.31
+0.02
(+0.11%)
After-Hours: 20:00
Immunome Enterprise Value : 1.556B for Oct. 29, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 29, 2026 | 1.556B |
| October 28, 2026 | 1.609B |
| October 27, 2026 | 1.611B |
| October 26, 2026 | 1.511B |
| October 23, 2026 | 1.522B |
| October 22, 2026 | 1.553B |
| October 21, 2026 | 1.523B |
| October 20, 2026 | 1.514B |
| October 19, 2026 | 1.384B |
| October 16, 2026 | 1.350B |
| October 15, 2026 | 1.455B |
| October 14, 2026 | 1.433B |
| October 13, 2026 | 1.476B |
| October 12, 2026 | 1.654B |
| October 09, 2026 | 1.699B |
| October 08, 2026 | 1.672B |
| October 07, 2026 | 1.647B |
| October 06, 2026 | 1.672B |
| October 05, 2026 | 1.883B |
| October 02, 2026 | 1.852B |
| October 01, 2026 | 1.851B |
| September 30, 2026 | 1.921B |
| September 29, 2026 | 1.964B |
| September 28, 2026 | 1.941B |
| September 25, 2026 | 1.910B |
| Date | Value |
|---|---|
| September 24, 2026 | 2.015B |
| September 23, 2026 | 2.231B |
| September 22, 2026 | 2.402B |
| September 21, 2026 | 2.325B |
| September 18, 2026 | 2.200B |
| September 17, 2026 | 2.196B |
| September 16, 2026 | 2.142B |
| September 15, 2026 | 2.198B |
| September 14, 2026 | 2.266B |
| September 11, 2026 | 2.280B |
| September 10, 2026 | 2.314B |
| September 09, 2026 | 2.444B |
| September 08, 2026 | 2.522B |
| September 04, 2026 | 2.517B |
| September 03, 2026 | 2.562B |
| September 02, 2026 | 2.581B |
| September 01, 2026 | 2.551B |
| August 31, 2026 | 2.590B |
| August 28, 2026 | 2.608B |
| August 27, 2026 | 2.756B |
| August 26, 2026 | 2.742B |
| August 25, 2026 | 2.814B |
| August 24, 2026 | 2.658B |
| August 21, 2026 | 2.716B |
| August 20, 2026 | 2.666B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 8.312B |
| Revolution Medicines, Inc. | 38.02B |
| Erasca, Inc. | 4.458B |
| Oncolytics Biotech, Inc. | 49.64M |
| Sangamo Therapeutics, Inc. | 41.42M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -73.13M |
| Total Expenses (Quarterly) | 73.13M |
| EPS Diluted (Quarterly) | -0.6456 |
| Earnings Yield | -13.81% |
| Normalized Earnings Yield | -13.40 |